Follow us on:

Linkedin Facebook

December 19, 2025

Norcros Plc

Norwegian school rethinking wall materials

A Norwegian school build showed how waterproof panels are replacing tiles in public construction...
Broker Ratings

Rocket Pharmaceuticals, Inc. (RCKT)

Broker Ratings

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 106% Potential Upside with Robust Buy Ratings

Broker Ratings

Upstream Bio, Inc. (UPB) Stock Analysis: Navigating a 57.40% Potential Upside in the Biotech Sector

Broker Ratings

Butterfly Network, Inc. (BFLY) Stock Analysis: A Promising 13.53% Upside in the Medical Devices Sector

Broker Ratings

Sonida Senior Living, Inc. (SNDA) Stock Analysis: A Deep Dive into the Healthcare Sector with a 25.9% Revenue Growth

Broker Ratings

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating a 15% Revenue Growth with Caution

Broker Ratings

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring an 89.81% Potential Upside in the Biotech Sector

Broker Ratings

CareDx, Inc. (CDNA) Stock Analysis: A 19.85% Upside Potential in the Healthcare Sector

Broker Ratings

Amylyx Pharmaceuticals (AMLX): Investor Outlook with a Promising 70% Upside Potential

Broker Ratings

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 93.97% Potential Upside Amid Strong Buy Ratings

Broker Ratings

Akebia Therapeutics, Inc. (AKBA) Rating Update: Analysts Eye 223% Upside Potential

Broker Ratings

Castle Biosciences, Inc. (CSTL) Stock Analysis: Navigating the Diagnostics Frontier with Analyst Confidence

Broker Ratings

Geron Corporation (GERN) Stock Analysis: High Analyst Ratings Signal a 168% Upside Potential

Broker Ratings

Kura Oncology, Inc. (KURA) Investor Outlook: Unveiling a Potential 235% Upside with Innovative Cancer Therapies

Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 190% Upside Potential Amidst Challenging Financials

Broker Ratings

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Sector with a Unique Market Position

Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS)

Broker Ratings

Valneva SE (VALN) Stock Analysis: Exploring the 58% Upside Potential in the Biotech Sector

Real Estate Credit Investments

RECI reports November NAV of 142.4p and maintains quarterly dividend

Real Estate Credit Investments reported a net asset value of 142.4 pence per share as at 30 November 2025, with the portfolio invested across 24 real estate credit positions valued at £281.9 million...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

January 12, 2024

Norcros Plc

Norwegian school rethinking wall materials

A Norwegian school build showed how waterproof panels are replacing tiles in public construction...
Broker Ratings

Rocket Pharmaceuticals, Inc. (RCKT)

Broker Ratings

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 106% Potential Upside with Robust Buy Ratings

Broker Ratings

Upstream Bio, Inc. (UPB) Stock Analysis: Navigating a 57.40% Potential Upside in the Biotech Sector

Broker Ratings

Butterfly Network, Inc. (BFLY) Stock Analysis: A Promising 13.53% Upside in the Medical Devices Sector

Broker Ratings

Sonida Senior Living, Inc. (SNDA) Stock Analysis: A Deep Dive into the Healthcare Sector with a 25.9% Revenue Growth

Broker Ratings

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating a 15% Revenue Growth with Caution

Broker Ratings

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring an 89.81% Potential Upside in the Biotech Sector

Broker Ratings

CareDx, Inc. (CDNA) Stock Analysis: A 19.85% Upside Potential in the Healthcare Sector

Broker Ratings

Amylyx Pharmaceuticals (AMLX): Investor Outlook with a Promising 70% Upside Potential

Broker Ratings

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 93.97% Potential Upside Amid Strong Buy Ratings

Broker Ratings

Akebia Therapeutics, Inc. (AKBA) Rating Update: Analysts Eye 223% Upside Potential

Broker Ratings

Castle Biosciences, Inc. (CSTL) Stock Analysis: Navigating the Diagnostics Frontier with Analyst Confidence

Broker Ratings

Geron Corporation (GERN) Stock Analysis: High Analyst Ratings Signal a 168% Upside Potential

Broker Ratings

Kura Oncology, Inc. (KURA) Investor Outlook: Unveiling a Potential 235% Upside with Innovative Cancer Therapies

Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 190% Upside Potential Amidst Challenging Financials

Broker Ratings

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Sector with a Unique Market Position

Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS)

Broker Ratings

Valneva SE (VALN) Stock Analysis: Exploring the 58% Upside Potential in the Biotech Sector

Real Estate Credit Investments

RECI reports November NAV of 142.4p and maintains quarterly dividend

Real Estate Credit Investments reported a net asset value of 142.4 pence per share as at 30 November 2025, with the portfolio invested across 24 real estate credit positions valued at £281.9 million...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

December 19, 2025

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple